Realistic expectations for the management of Alzheimer's disease

European Neuropsychopharmacology

Volumn 9, Issue SUPPL. 2, 1999, Pages

  Brodaty, Henry ^a  

^a PRINCE OF WALES HOSPITAL   (Australia)

Author keywords

Alzheimer's disease; Expectation; Therapy

Indexed keywords

CHOLINE; CHOLINESTERASE INHIBITOR; LINOPIRDINE; NICOTINIC AGENT; PHOSPHATIDYLCHOLINE;

ALZHEIMER DISEASE; BEHAVIOR DISORDER; COGNITIVE DEFECT; CONFERENCE PAPER; HUMAN; PRIORITY JOURNAL; RISK FACTOR; TREATMENT OUTCOME;

AGED; ALZHEIMER DISEASE; COMORBIDITY; HUMANS; PREVALENCE; RISK FACTORS;

EID: 0032946725     PISSN: 0924977X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0924-977X(98)00044-3     Document Type: Conference Paper

References (76)

1. Andersen J.K., Jurma O.P. Use of genetically engineered mice as models for understanding neurodegenerative disease. J. Am. Geriatr. Soc. 44:1996;717-722.
2. Andersen K., Launer L.J., Ott A., Hoes A.W., Breteler M.M.B., Hoffman A. Do nonsteroidal anti-inflammatory drugs decrease the risk for Alzheimer's disease: The Rotterdam study. Neurology. 45:1995;1441-1445.
3. Beckett L.A., Bennett D.A., Field T., Evans D.A. Anti-inflammatory drug use and risk of incident Alzheimer's disease in a defined community population. Neurobiol. Aging. 17:1996;S80.
4. Breteler M.M., Van Duijn C.M., Chandra V., Fratiglioni L., Graves A.B., Heyman A., Jorm A.F., Kokmen E., Kondo K., Mortimer J.A. Medical history and the risk of Alzheimer's disease: A collaborative re-analysis of Case Control Studies (EURODEM Risk Factors Research Group). Int. J. Epidemiol. 20:1991;S36-S42.
5. Breteler M.M.B., Claus J.J., Van Duijn C.M., Launer L.J., Hofman A. Epidemiology of Alzheimer's disease. Am. J. Epidemiol. 14:1992;59-82.
6. Breteler M.M.B., Claus J.J., Grobbee D.E., Hofman A. Cardiovascular disease and distribution of cognitive function in elderly people: The Rotterdam study. BMJ. 308:1994;1604-1608.
7. Brodaty, H., 1992. Carers: Training informal carers. In: Arie, T. (Ed.), Recent Advances in Psychogeriatrics, Churchill Livingstone, Edinburgh, pp. 163-172.
8. Brodaty H. Carers and behavioural disturbance of dementia. Int. Psychogeriatr. 8(Suppl. 3):1996;455-458.
9. Brodaty H., Gresham M. Effects of a training programme to reduce stress in carers of patients with dementia. BMJ. 299:1989;1375-1379.
10. Brodaty H., Peters K.E. Cost effectiveness of a training program for dementia carers. Int. Psychogeriatr. 3:1991;11-22.
11. Brodaty H., Luscombe G. Psychological morbidity in caregivers is associated with depression in patients with dementia. Alzheimer's Disease and Associated Disorders. 12:1998;62-70.
12. Brodaty H., McGilchrist C., Harris L., Peters K.E. Time until institutionalization and death in patients with dementia. Arch. Neurol. 50:1993;643-650.
13. Brodaty H., Gresham M., Luscombe G. The Prince Henry Hospital caregivers' training programme. Int. J. Geriatr. Psychiatry. 12(2):1997;183-192.
14. Broe G.A., Henderson A.S., Creasey H., McCusker E., Korten A.E., Jorm A.F., Longley W., Anthony J.C. A case-control study of Alzheimer's disease in Australia. Neurology. 40:1990;1698-1707.
15. Burke W.J., Miller J.P., Rubin E.H., Morris J.C., Coben L.A., Duchek J., Wittels I.G., Berg L. The reliability of the Washington University Clinical Dementia Rating. Arch. Neurol. 45:1988;31-32.
16. Carrier, L., Brodaty, H., 1996. Mood and behaviour management. In: Gauthier, S. (Ed.), Clinical Diagnosis and Management of Alzheimer's Disease, Martin Dunitz, London, pp. 205-220.
17. Collier, J.A.B., Longmore, J.M., Hodgetts, T.J., 1995. Oxford Handbook of Clinical Specialties, 4th edn., Oxford University Press, Oxford, p. 426.
18. Cummings J.L., Kaufer D.I. Neuropsychiatric aspects of Alzheimer's disease: The cholinergic hypothesis revisited. Neurology. 47:1996;876-883.
19. Davies P., Terry R.D. Cortical somatostatin-like immunoreactivity in cases of Alzheimer's disease and senile dementia of the Alzheimer's type. Neurobiol. Aging. 2:1981;9-14.
20. Dent, O., 1996. Presentation at Lancet Conference on Alzheimer's Disease, Edinburgh, April 1996.
21. Eagger S., Richards M., Levy R. Long-term effects of tacrine in Alzheimer's disease: An open study. Int. J. Geriatr. Psychiat. 9:1994;643-647.
22. Evans D.A., Beckett L.A., Albert M.S., Hebert L.E., Scherr P.A., Funkenstein H.H., Taylor J.O. Level of education and change in cognitive function in a community population of older persons. Ann. Epidemiol. 31:1993;71-77.
23. Feldman, H., Gracon, S., 1996. Alzheimer's disease: Symptomatic drugs under development. In: Gauthier, S. (Ed.), Clinical Diagnosis and Management of Alzheimer's Disease, Martin Dunitz, London, pp. 239-259.
24. Fitz A.G., Teri L. Depression cognition and functional ability inpatients with Alzheimer's disease. J. Am. Geriatr. Soc. 42:1994;186-191.
25. Galasko D., Edland S.D., Morris J.C., Clark C., Mohs R., Koss E. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part XI. Clinical milestones in patients with Alzheimer's disease followed over three years. Neurology. 45:1995;1451-1455.
26. Gottfries C.G. Therapy options in Alzheimer's disease. Br. J. Clin. Pract. 48:1994;327-330.
27. Graves, A.B., Kukull, W.A., 1994. The epidemiology of dementia. In: Morris, J. (Ed.), Handbook of Dementing Illnesses, Marcel Dekker, New York, pp. 23-70.
28. Gray, J.A., Gauthier, S., 1996. Stabilization approaches to Alzheimer's disease. In: Gauthier, S. (Ed.), Clinical Diagnosis and Management of Alzheimer's Disease, Martin Dunitz, London, pp. 261-267.
29. Henderson A.S., Jorm A.F., Korten A.E., Creasey H., McCusker E., Broe G.A., Longley W., Anthony J.C. Environmental risk factors for Alzheimer's disease: Their relationship to age of onset and to familial or sporadic types. Psychol. Med. 22:1992;429-436.
30. Hinchcliffe A.C., Hyman I.L., Blizard B., Livingston G. Behavioural complications of dementia - Can they be treated? Int. J. Geriatr. Psychiat. 10:1995;839-847.
31. Jorm, A.F., 1990. The Epidemiology of Alzheimer's Disease and Related Disorders, Chapman and Hall, London.
32. Jorm A.F., Van Duijn C.M., Chandra V., Fratiglioni L., Graves A.B., Heyman A., Kokmen E., Kondo K., Mortimer J.A., Rocca W.A. Psychiatric history and related exposures as risk factors for Alzheimer's disease: A collaborative re-analysis of case-control studies. Int. J. Epidemiol. 20(Suppl. 2):1991;S43-47.
33. Kaufer D.I., Cummings J.L., Christine G. Effect of tacrine on behavioural symptoms in Alzheimer's disease: An open-label study. J. Geriatr. Psychiatry Neurol. 9:1996;1-6.
34. Knapp M.J., Knopman D.S., Solomon P.R., Pendlebury W.W., Davis C.S., Gracon S.I. A 30-week randomised controlled trial of high-dose tacrine in patients with Alzheimer's disease. JAMA. 271:1994;985-991.
35. Knight B.G., Lutzky S.M., Macofsky-Urban F. A meta-analytic review of interventions for caregiver distress: Recommendations for future research. Gerontologist. 33:1993;240-248.
36. Larson E.B., Kukull W.A. Prevention of Alzheimer disease: A perspective based on successes in the prevention of other chronic diseases. Alzheimer Dis. Assoc. Disord. 10(1):1996;9-12.
37. Lautenschlager N.T., Cupples L.A., Rao V.S. Risk of dementia among relatives of Alzheimer's disease patients in the MIRAGE study: What is in store for the oldest old? Neurology. 46:1996;641-650.
38. Leber P. Observations and suggestions on antidementia drug development Alzheimer. Dis. Assoc. Disord. 10(1):1996;31-35.
39. Levy R., Eagger S., Griffiths M., Perry E., Honavar M., Dean A., Lontas P. Lewy bodies and response to tacrine in Alzheimer's disease. Lancet. 343:1994;176.
40. Locke P.A., Conneally P.M., Tanzi R.E., Gusella J.F., Haines J.L. Apolipoprotein E4 allele and Alzheimer disease: Examination of allelic association and effect on age at onset in both early- and late-onset cases. Genet. Epidemiol. 12:1995;83-92.
41. Masters, C.L., Beyreuther, K., 1994. Alzheimer's disease: A clever definition of the genetic components, Alzheimer's Association Australia, 4th Natl. Conf., Sydney, 10-13 April 1994, Alzheimer's Association (Australia), Sydney, pp. 22-25.
42. Mayeux R. Development of a national prospective study of Alzheimer's disease. Alzheimer Dis. Assoc. Disord. 10(1):1996;38-44.
43. Mittelman M.S., Ferris S.H., Steinberg G., Shulman E., Mackell J.A., Ambinder A., Cohen J. An intervention that delays institutionalization of Alzheimer's disease patients: Treatment of spouse-caregivers. Gerontologist. 33:1993;730-740.
44. Mittelman M.S., Ferris S.H., Shulman E., Steinberg G., Levin B. A family intervention to delay nursing home placement of patients with Alzheimer disease. A randomised controlled trial. JAMA. 276(21):1996;1725-1731.
45. Morrison, A.S., 1992. Screening in Chronic Disease, Oxford University Press, New York.
46. Mortimer, J.A., 1994. What are the risk factors for dementia? In: Huppert, F., Brayne, C., O'Connor, D.W., Dementia and Normal Aging, Cambridge University Press, pp. 208-229.
47. Mortimer J.A., Fortier I., Pepin E.P., Gauvreau D. Sensory loss as a predictor of dementia and questionable dementia in a community study of elderly persons. Alzheimer Dis. Assoc. Disord. 17:1996;S79.
48. Nitsch R.M., Slack B.E., Wurtman R.J., Growdon J.H. Release of Alzheimer amyloid precursor derivatives stimulated by activation of muscarinic acetylcholine receptors. Science. 258:1992;304-307.
49. O'Donnell B.F., Drachman D.A., Barnes H.J., Peterson K.E., Swearer J.M., Lew R.A. Incontinence and troublesome behaviors predict institutionalization in dementia. J. Geriatr. Psychiatry Neurol. 5:1992;45-52.
50. Ohkura T., Isse K., Akazawa K., Hamamoto M., Yaoi Y., Hagino N. Evaluation of estrogen treatment in female patients with dementia of the Alzheimer type. Endocrine J. 41:1994;361-371.
51. Paganini-Hill A., Hendersen V. Estrogen deficiency and risk of Alzheimer's disease in women. Am. J. Epidemiol. 140:1994;256-261.
52. Peabody C.A., Davis H., Berger P.A. Desamino-D-arginine Vasopressin (DDAVP) in Alzheimer's disease. Neurobiol. Aging. 7:1986;301-303.
53. Reifler B.V., Teri L., Raskind M., Veith R., Barnes R., White E., McLean P. Double blind trial of imipramine in Alzheimer's disease patients with and without depression. Am. J. Psychiatry. 146:1989;45-49.
54. Reisberg B., Borenstein J., Salbo S.P., Ferris S.H., Franssen E., Georgotas A. Behavioral symptoms in Alzheimer's disease: Phenomenology and treatment. J. Clin. Psychiatry. 48(Suppl.):1987;9-15.
55. Robinson D., Friedman L., Marcus R., Tinklenberg J., Yesavage J. Estrogen replacement therapy and memory in older women. J. Am. Geriatr. Soc. 42:1994;919-922.
56. Rogers S., Friedhoff L.T. The efficacy and safety of donepezil in patients with Alzheimer's disease: Results of a US multicentre, randomised, double-blind, placebo-controlled trial. Dementia. 7:1996;293-303.
57. Rogers S.L., Friedhoff L.T. Long-term efficacy and safety of donepezil in the treatment of Alzheimer's disease: An interim analysis of the results of a US multicentre open label extension study. Eur. Neuropsychopharmacol. 8:1998;67-75.
58. Rogers, S.L., Farlow, M.R., Doody, R.S., Mohs, R.C., Friedhoff, L.T. and the Donepezil Study Group, 1998. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease, Neurology 50, 136-145.
59. Sano, M., Ernesto, C., Klauber, M.R., Schafer, K., Woodbury, P., Thomas, R., Grundman, M., Growdon, J., Thal, L.J. and members of the Alzheimer's Disease Cooperative Study, 1996. Rationale and design of a multicenter study of selegiline and α-tocopherol in the treatment of Alzheimer disease using novel clinical outcomes. Alzheimer Dis. Assoc. Disord. 10, 132-140.
60. Sano M., Ernesto C., Thomas R.G., Klauber M.R., Schafer K., Grundman M., Woodbury P., Growdon J., Cotman C.W., Pfeiffer E., Schneider L.S., Thal L.J. A controlled trial of selegiline, alpha-tocopherol or both as treatment for Alzheimer's disease. N. Engl. J. Med. 336:1997;1216-1222.
61. Saunders A.M., Strittmatter W.J., Schmechel D.E., George-Hyslop P.H., Pericak-Vance M.A., Joo S.H., Rosi B.L., Gusella J.F., Crapper-MacLachlan D.R., Alberts M.J. Association of apolipoprotein E allele (epsilon) 4 with late onset Alzheimer's disease. Neurology. 43:1993;1467-1472.
62. Schneider L.S., Farlow M.R. Predicting response to cholinesterase inhibitors: Possible approaches. CNS Drugs. 4:1995;114-124.
63. Selkoe D.J. Alzheimer's disease: Genotypes, phenotypes, and treatments. Science. 275(5300):1997;630-631.
64. Shumaker, S., Rapp, S., 1996. Hormone therapy in dementia prevention: The Women's Health Initiative Memory Study. Neurobiol. Aging 17 (Suppl. 4), S9(34).
65. Snowdon D.A., Kemper S.J., Mortimer J.A., Greiner L.H., Wekstein D.R., Markesbery W.R. Linguistic ability in early life and cognitive function and Alzheimer's disease in late life: Findings from the Nun Study. JAMA. 275:1996;528-533.
66. Steele C., Rovner B., Chase G.A., Folstein M. Psychiatric symptoms and nursing home placement of patients with Alzheimer's disease. Am. J. Psychiatry. 147:1990;577-587.
67. Stern Y., Gurland B., Tatemichi T., Tang M.X., Wilder D., Mayeux R. Influence of education and occupation on the incidence of Alzheimer's disease. JAMA. 271(13):1994;1004-1010.
68. Teri L. Behavioral treatment of depression in patients with dementia. Alzheimer Dis. Assoc. Disord. 8(3):1994;66-74.
69. Teri L., Logsdon R.G., Uomoto J., McCurry S.M. Behavioral treatment of depression in dementia patients: A controlled clinical trial. J. Gerontol. B. Psychol. Sci. Soc. Sci. 52B(4):1997;159-166.
70. Thal L. Potential prevention strategies for Alzheimer disease. Alzheimer Dis. Assoc. Disord. 10(1):1996;6-8.
71. Wagstaff A.J., McTavish D. Tacrine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in Alzheimer's disease. Drugs Aging. 4:1994;510-540.
72. Woods, R.T., 1996a. Psychological 'therapies' in dementia. In: Woods, R.T. (Ed.), Handbook of the Clinical Psychology of Ageing, John Wiley, Chichester, pp. 575-600.
73. Woods, R.T., 1996b. Institutional care. In: Woods, R.T. (Ed.), Handbook of the Clinical Psychology of Ageing, John Wiley, Chichester, pp. 369-388.
74. Wragg R.E., Jeste D.V. Overview of depression and psychosis in Alzheimer's disease. Am. J. Psychiatry. 145:1989;577-587.
75. Zanetti O., Frisoni G.B., De Leo D., Buono M.D., Bianchetti A., Trabucchi M. Reality orientation therapy in Alzheimer's disease: Useful or not? A controlled study. Alzheimer Dis. Assoc. Disord. 9(3):1995;132-138.
76. Zhang M.Y., Katzman R., Salmon D., Jin H., Cai G.J., Wang Z.Y., Qu G.Y., Grant I., Yu E., Vevy P. The prevalence of dementia and Alzheimer's disease in Shanghai, China: Impact of age, gender and education. Ann. Neurol. 27:1990;428-437.